Astrazeneca's Camizestrant cleared in the EU, Enhertu and Datroway pick up fresh recommendations
26th May 2026 08:16
(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that its breast cancer treatment camizestrant has secured EU approval, while its Enhertu and Datroway drug candidates also received fresh regulatory recommendations in Europe and the US.
Read moreCiti sees buying opportunity at AstraZeneca after recent falls
18th May 2026 11:21
(Sharecast News) - Analysts at Citi have reiterated a 'buy' rating on AstraZeneca and a 'neutral' on GSK following the European pharma sector's first-quarter earnings season.
Read moreAstraZeneca secures US approval for two drugs
18th May 2026 09:06
(Sharecast News) - Two AstraZeneca drugs have been given the green light in America to treat high blood pressure and breast cancer, the blue chip confirmed on Monday.
Read moreLondon close: Stocks mixed as investors mull longer Hormuz blockade
1st May 2026 14:13
(Sharecast News) - London stocks ended mixed on Friday as investors weighed ongoing concerns about the Strait of Hormuz blockade against resilient domestic data, after the Bank of England warned that inflation could breach 6% next year in a worst-case scenario linked to higher oil prices.
Read moreAstraZeneca Q1 revenues grow, reiterates FY26 constant currency guidance
29th Apr 2026 07:16
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that it had delivered solid revenue growth and a series of positive late‑stage trial readouts in the first quarter, reinforcing confidence in its 2030 ambitions.
Read moreAstraZeneca's asthma maintenance treatment receives US FDA approval
28th Apr 2026 07:11
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it asthma maintenance treatment Breztri Aerosphere had received approval from the US Food and Drug Administration for adults and adolescents aged 12 and over.
Read moreAstraZeneca's Saphnelo Pen gets green light from US FDA
27th Apr 2026 07:12
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its systemic lupus erythematosus treatment Saphnelo (anifrolumab) hsd received US Food and Drug Administration approval for self‑administration via a once‑weekly autoinjector, the Saphnelo Pen.
Read moreAstraZeneca receives positive high level results from Phase III I CAN trial
21st Apr 2026 07:07
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that high‑level results from an interim analysis of its Phase III I CAN trial showed Ultomiris had met its primary endpoint, delivering a statistically significant and meaningful reduction in proteinuria in adults with IgA nephropathy at risk of disease progression.
Read moreAstraZeneca's COPD candidate succeeds in twin Phase III studies
27th Mar 2026 07:07
(Sharecast News) - Drugmaker AstraZeneca said on Friday that its monoclonal antibody tozorakimab had met the primary endpoint in both of its Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease.
Read moreAstraZeneca's Calquence leukaemia treatment gets US FDA approval
20th Feb 2026 10:40
(Sharecast News) - AstraZeneca said on Friday that the US Food and Drug Administration has approved its 'Calquence', or acalabrutinib, in combination with venetoclax as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic lymphocytic leukaemia and small lymphocytic lymphoma in the first-line setting.
Read moreShore Capital lowers AstraZeneca to 'hold'
13th Feb 2026 13:59
(Sharecast News) - Shore Capital downgraded drugmaker AstraZeneca from 'buy' to 'hold' on Friday, stating the drugmaker's near‑term earnings outlook looked less favourable despite what it called "exceptional" R&D delivery.
Read moreAnnual sales, profits jump at AstraZeneca
10th Feb 2026 07:29
(Sharecast News) - AstraZeneca posted a spike in full-year revenues and earnings on Tuesday, boosted by strong demand for its cancer drugs, and forecast further growth in the current year.
Read moreFDA rejects self-injectable version of AstraZeneca lupus drug
3rd Feb 2026 07:34
(Sharecast News) - The US health regulator has rejected an application by AstraZeneca to launch a self-injectable version of its lupus treatment Saphnelo, the drugs giant confirmed on Tuesday.
Read moreAstrazeneca's Imfinzi receives EU recommendation from CHMP
2nd Feb 2026 07:29
(Sharecast News) - Drugmaker Astrazeneca said on Monday that its gastric and gastroesophageal junction cancer treatment, Imfinzi, has been recommended for approval in the European Union by the Committee for Medicinal Products for Human Use (CHMP).
Read moreAstraZeneca strikes collaborative agreement with CSPC Pharmaceuticals
30th Jan 2026 07:03
(Sharecast News) - Drugmaker Astrazeneca said on Friday that it has expanded its weight‑management pipeline after striking a strategic collaboration with CSPC Pharmaceuticals to develop a series of next‑generation obesity and type‑2 diabetes therapies.
Read more